Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of Pembrolizumab and Lenvatinib Combination Therapy in Patients With Previously Treated Advanced Gastroesophageal Adenocarcinoma

NCT05041153 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT05041153
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05041153 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of Pembrolizumab and Lenvatinib Combination Therapy in Patients With Previously Treated Advanced Gastroesophageal Adenocarcinoma
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Active, not recruiting
Start date
February 14, 2022
Completion date
December 30, 2026
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gastric adenocarcinoma, advanced gastroesophageal junction adenocarcinoma, clinical stage iii gastric cancer ajcc v8, clinical stage iii gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iv gastric cancer ajcc v8, clinical stage iv gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iva gastric cancer ajcc v8, clinical stage iva gastroesophageal junction adenocarcinoma ajcc v8, clinical stage ivb gastric cancer ajcc v8, clinical stage ivb gastroesophageal junction adenocarcinoma ajcc v8, metastatic gastric adenocarcinoma, metastatic gastroesophageal junction adenocarcinoma, pathologic stage iii gastric cancer ajcc v8, pathologic stage iii gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iiia gastric cancer ajcc v8, pathologic stage iiia gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iiib gastric cancer ajcc v8, pathologic stage iiib gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iiic gastric cancer ajcc v8, pathologic stage iv gastric cancer ajcc v8, pathologic stage iv gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iva gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage ivb gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage iii gastric cancer ajcc v8, postneoadjuvant therapy stage iii gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage iiia gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage iiib gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage iv gastric cancer ajcc v8, postneoadjuvant therapy stage iv gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage iva gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage ivb gastroesophageal junction adenocarcinoma ajcc v8, unresectable gastric adenocarcinoma, unresectable gastroesophageal junction adenocarcinoma